S2045796021000044jra 1..11
Y. H. Liao,B. F. Fan,H. M. Zhang,L. Guo,Y. Lee,W. X. Wang,W. Y. Li,M. Q. Gong,L. M. W. Lui,L. J. Li,C. Y. Lu,R. S. McIntyre
2021-01-01
Abstract:Aims. The coronavirus disease 2019 (COVID-19) pandemic represents an unprecedented threat to mental health. Herein, we assessed the impact of COVID-19 on subthreshold depressive symptoms and identified potential mitigating factors. Methods. Participants were from Depression Cohort in China (ChiCTR registry number 1900022145). Adults (n = 1722) with subthreshold depressive symptoms were enrolled between March and October 2019 in a 6-month, community-based interventional study that aimed to prevent clinical depression using psychoeducation. A total of 1506 participants completed the study in Shenzhen, China: 726 participants, who completed the study between March 2019 and January 2020 (i.e. before COVID-19), comprised the ‘wave 1’ group; 780 participants, who were enrolled before COVID-19 and completed the 6-month endpoint assessment during COVID-19, comprised ‘wave 2’. Symptoms of depression, anxiety and insomnia were assessed at baseline and endpoint (i.e. 6-month follow-up) using the Patient Health Questionnaire-9 (PHQ-9), Generalised Anxiety Disorder-7 (GAD-7) and Insomnia Severity Index (ISI), respectively. Measures of resilience and regular exercise were assessed at baseline. We compared the mental health outcomes between wave 1 and wave 2 groups. We additionally investigated how mental health outcomes changed across disparate stages of the COVID19 pandemic in China, i.e. peak (7–13 February), post-peak (14–27 February), remission plateau (28 February−present). Results. COVID-19 increased the risk for three mental outcomes: (1) depression (odds ratio [OR] = 1.30, 95% confidence interval [CI]: 1.04–1.62); (2) anxiety (OR = 1.47, 95% CI: 1.16– 1.88) and (3) insomnia (OR = 1.37, 95% CI: 1.07–1.77). The highest proportion of probable depression and anxiety was observed post-peak, with 52.9% and 41.4%, respectively. Greater baseline resilience scores had a protective effect on the three main outcomes (depression: OR = 0.26, 95% CI: 0.19–0.37; anxiety: OR = 1.22, 95% CI: 0.14–0.33 and insomnia: OR = 0.18, 95% CI: 0.11–0.28). Furthermore, regular physical activity mitigated the risk for depression (OR = 0.79, 95% CI: 0.79–0.99). Conclusions. The COVID-19 pandemic exerted a highly significant and negative impact on symptoms of depression, anxiety and insomnia. Mental health outcomes fluctuated as a function of the duration of the pandemic and were alleviated to some extent with the observed decline in community-based transmission. Augmenting resiliency and regular exercise provide an opportunity to mitigate the risk for mental health symptoms during this severe public health crisis. Introduction The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented mental health threat globally as a consequence of the fear of contraction, as well as government reaction to containing community spread (e.g. economic shut down, unemployment). Replicated studies from around the world have reported on the increased prevalence of mental disorders as a result of COVID-19, including depression, anxiety and insomnia (i.e. prevalence of 10.6% −50.7%, 10.4%−44.7% and 33.9%−36.1%, respectively) (Lai et al., 2020; Liu et al., 2020; Potloc Study, 2020; Wang et al., 2020b; Zhang et al., 2020). Furthermore, as a consequence of heightened anxiety due to the pandemic, along with the economic shock and stress related to quarantine, an increase in suicide is expected in Canada, the United States and possibly other countries (McIntyre and Lee, 2020a, 2020b). Subthreshold depressive symptoms (i.e. not meeting minimum diagnostic threshold for a major depressive episode) are an important risk indicator for incident major depressive disorder (MDD). Persons with subthreshold depressive symptoms are approximately twice as likely to be diagnosed with MDD relative to those without (Rodríguez et al., 2012; Lee et al., 2019). In the general population, the absolute risk of conversion to MDD from subthreshold depressive symptoms (excluded lifetime MDD) ranged from 0.012 to 0.096 per 100 person years (Cuijpers and Smit, 2004). A 13-year prospective study in communities indicated the mean age of first depressive episode in people with subthreshold depressive symptoms was 34 years, which was similar with the age onset in MDD (Chen et al., 2000). It has been estimated that approximately 2.9%−9.9% of adults in primary care and 1.4% −17.2% of adults in community settings manifest subthreshold depressive symptoms (Lee et al., 2019). Recent studies have raised concerns about populations that are more vulnerable to the detrimental mental health effects of the COVID-19 pandemic. For example, people with mental health conditions may be more substantially influenced by the emotional distress brought on by the COVID-19 pandemic, resulting in relapses or worsening of pre-existing mental health condition(s) compared with the general population (Yao et al., 2020). In addition, psychological response may change with fluctuations in the epidemic and clinical knowledge improvement. For example, a related longitudinal study investigating psychological adaptions during the severe acute respiratory syndrome (SARS) outbreak suggested that increasing knowledge and understanding of SARS could improve mental health outcomes (Su et al., 2007). The primary aim of this longitudinal study is to evaluate the impact of COVID-19 in a subthreshold depressive symptom population. The secondary aim of this study is to explore potential predictors of mental health improvement to recommend feasible intervention under acute stress. Methods Study design and participants Data in this study were derived from an ongoing longitudinal, population-based study for the early identification, treatment, prevention and management of depression and subthreshold depression (Depression Cohort in China [DCC] study, ChiCTR registry number 1900022145). Individuals were identified via a standardised community-based screening protocol for the detection of depression in two communities, 21 primary care centres, one general hospital and one specialised mental health hospital in Shenzhen, China. Participants aged 18–64 years meeting criteria for subthreshold depressive symptoms were enrolled between March 2019 and October 2019. Subthreshold depressive symptoms were operationalised as having a Patient Health Questionnaire-9 (PHQ-9) total score of ⩾ 5 without current or history of MDD. The follow-up period was 6 months. Exclusion criteria were: (1) a diagnosis of MDD, severe psychiatric disorders (i.e. schizophrenia, bipolar disorder, schizoaffective mental disorder, paranoid mental disorder, mental disorder caused by epilepsy, mental retardation) and/or alcohol or drug addiction disorder, (2) pregnant or perinatal women, (3) not being fluent in mandarin and (4) not having a plan to leave Shenzhen within 6 months. Psychiatric diagnoses were confirmed by trained psychiatrists using the Mini International Neuropsychiatric Interview (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria). The study protocol was approved by the Ethical Review Boards of all the participating centres, and all the participants gave written informed consent. A total of 3715 people were screened, of which 2645 (71.2%) were from 21 primary care centres, 468 (12.6%) were from two communities, 368 (9.9%) were from a general hospital and 234 (6.3%) people were from a specialised mental health hospital. A total of 1722 participants were enrolled in the study between March 2019 and October 2019. Of the 1722 participants, 1506 (87.5%) participants completed the 6-month study; 216 participants were lost during follow-up (i.e. withdrew from study, n = 71; did not complete questionnaires, n = 29; unable to contact, n = 116). Of the 1506 participants with endpoint data, participants who completed the baseline and 6-month follow-up before the COVID-19 outbreak were classified into the ‘wave 1’ group (i.e. from March 2019 to January 2020) and participants who completed baseline before the COVID-19 outbreak but completed the 6-month follow-up during the COVID-19 outbreak were classified into ‘wave 2’ group (i.e. from August 2019 to April 2020). BRIDGES integrate care The DCC study used a Building Bridges to Integrate Care (BRIDGES) model, which used the Toronto-based BRIDGES model as a reference (Bhattacharyya et al., 2016), and linked primary care centres, specialist hospitals and community care in accordance to the health system in Shenzhen. In this healthcare model, psychiatrists from specialist hospitals trained general practitioners (GPs) in primary care centres to identify, and provided treatment and education programmes for participants with subthreshold depressive symptoms. Project managers, who were public health doctors, from specialist hospitals supervised and ensured the quality administration of the intervention provided by the GPs. Both wave 1 cohort and wave 2 cohort received the same usual care, including (1) delivering project introduction brochures; (2) sending a short message service (SMS) monthly that provide mental health education (i.e. mental health stereotypes, depression treatments and stress arrangement); (3) telephonebased mental health consult every 6 months (i.e. mental health condition communication and updated information of psychiatric evaluation in study); (4) referral and face-to-face psychiatric evaluation for participants with PHQ-9 > 9 or for those with an active request to see a doctor. Outcome and covariates Depression and anxiety symptoms in the past 2 weeks were assessed using the Patient Health Questionnaire-9 (PHQ-9, Cronbach’s α = 0.89) and Generalised Anxiety Disorder-7 (GAD-7, Cronbach’s α = 0.89), respectively (Kurt Kroenke and Williams, 2001; Löwe et al., 2008). The severity of depression and anxiety was divided into minimal, mild, moderate and severe based on a score of 0–4, 5–9, 10–14 (10–13 for anxiety) and 15–27 (14–21 for anxiety), respectively (Kurt Kroenke and William